BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30131003)

  • 1. Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee.
    Compostella A; Affinita MC; Casanova M; Milano GM; Scagnellato A; Dall'Igna P; Chiaravalli S; Pierobon M; Manzitti C; Zanetti I; Schiavetti A; Sorbara S; Mura RM; Ruggiero A; Ferrari A; Bisogno G
    Tumori; 2019 Apr; 105(2):138-143. PubMed ID: 30131003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: a phase II window trial of the cooperative soft tissue sarcoma group.
    Bochennek K; Dantonello T; Koscielniak E; Claviez A; Dirksen U; Sauerbrey A; Beilken A; Klingebiel T
    Klin Padiatr; 2013 Nov; 225(6):309-14. PubMed ID: 23946091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
    J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
    Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
    Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
    Heinz AT; Ebinger M; Schönstein A; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter MW; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Rößler J; Ljungman G; Klingebiel T; Koscielniak E; Sparber-Sauer M;
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30363. PubMed ID: 37066598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO; Lyden ER; Breitfeld PP; Qualman SJ; Wharam MD; Meyer WH
    J Clin Oncol; 2004 Apr; 22(8):1398-403. PubMed ID: 15007087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA; Castellano A; Ilari I; Garganese MC; Natali G; Inserra A; De Vito R; Ravà L; De Pasquale MD; Locatelli F; Donfrancesco A; Jenkner A
    Eur J Cancer; 2011 Mar; 47(4):572-8. PubMed ID: 21112775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS; Lyden E; Breneman J; Wiener E; Teot L; Meza J; Crist W; Vietti T
    J Clin Oncol; 2001 Jan; 19(1):213-9. PubMed ID: 11134215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma.
    Meazza C; Casanova M; Zaffignani E; Luksch R; Podda M; Favini F; Catania S; Biassoni V; Morosi C; Ferrari A
    Med Oncol; 2009; 26(1):67-72. PubMed ID: 18679836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing actinomycin-D with Carboplatin for newly diagnosed rhabdomyosarcoma.
    Sezgin G; Acipayam C; Bayram I; Ozkan A; Kupeli S; Tanyeli A
    Asian Pac J Cancer Prev; 2015; 16(8):3351-4. PubMed ID: 25921143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
    Devadas SK; Banavali S
    Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
    Kaufmann SH; Karp JE; Letendre L; Kottke TJ; Safgren S; Greer J; Gojo I; Atherton P; Svingen PA; Loegering DA; Litzow MR; Sloan JA; Reid JM; Ames MM; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Sep; 11(18):6641-9. PubMed ID: 16166443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.